TruSight Tumor 170

Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample. Read More...
Select Product(s)

TruSight Tumor 170 Kit, For Use with NextSeq (24 Samples)

OP-101-1003

Price
 
 

TruSight Tumor 170 Kit (24 Samples)

OP-101-1004

Price
 
 

TruSight Tumor 170 Kit, For Use with NextSeq plus Watson for Genomics

20018621

Price
 
 

TruSight Tumor 170 Kit plus Watson for Genomics

20018622

Price
 
 

Product Highlights

TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.

  • Comprehensive Coverage of Cancer-Related Variants
    Assessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications in one assay using DNA and RNA creates efficiencies in sample usage, time, and cost.
  • Accurate Results from Low-Quality Samples1
    Variant detection with as little as 40 ng DNA and RNA input, and as low as 5% mutant allele frequency, maximizes the results from precious formalin-fixed paraffin-embedded (FFPE) samples.
  • Integrated, Streamlined Workflow
    DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis.

Specifications

Method-Specific Workflow Example

 

Scientific Posters

AACR 2017: TruSight Tumor 170 and Tumor Mutational Burden

Results of analysis indicate that TruSight Tumor 170, with comprehensive coverage of cancer-related genes, shows high concordance with whole exome sequencing for accurate assessment of tumor mutational burden.

Learn More

AACR 2017: TruSight Tumor 170 and Solid Tumor Profiling Analytical Performance with FFPE Samples

Standard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85% of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.

Learn More

AACR 2017: TruSight Tumor 170 for Small Nucleotide Variations and Gene Amplifications in FFPE DNA Samples

TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.

Learn More

AACR 2017: TruSight Tumor 170 for Fusions and Splice Variants in FFPE RNA Tumor Samples

Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.

Learn More

Related Products

Image Source
TruSight Tumor 15

Focused sequencing panel to assess 15 genes that are commonly mutated in solid tumors in a single assay, with a simple, rapid workflow.


Image Source
TruSight RNA Pan-Cancer

Targeting 1385 cancer genes for gene expression, variant, and fusion detection studies in many RNA sample types including blood, bone marrow, and FFPE.


Image Source
TruSight RNA Fusion Panel

Provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer research samples.


References
  1. Beta study. Data on file. March 2017.